Novel agents for the treatment of childhood leukemia: an update
dc.contributor.author | Eryilmaz, Ertugrul | |
dc.contributor.author | Canpolat, Cengiz | |
dc.date.accessioned | 2023-02-21T12:32:53Z | |
dc.date.available | 2023-02-21T12:32:53Z | |
dc.date.issued | 2017-01-01 | |
dc.description.abstract | Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15\% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia. | |
dc.description.pages | 3299-3306 | |
dc.description.volume | 10 | |
dc.identifier.doi | 10.2147/OTT.S126368 | |
dc.identifier.uri | https://hdl.handle.net/11443/1308 | |
dc.identifier.uri | http://dx.doi.org/10.2147/OTT.S126368 | |
dc.identifier.wos | WOS:000404879500001 | |
dc.publisher | DOVE MEDICAL PRESS LTD | |
dc.relation.ispartof | ONCOTARGETS AND THERAPY | |
dc.subject | acute lymphoblastic leukemia | |
dc.subject | acute myeloid leukemia | |
dc.subject | pediatric leukemia | |
dc.subject | systemic therapies | |
dc.title | Novel agents for the treatment of childhood leukemia: an update | |
dc.type | Article |